Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

GlaxoSmithKline Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (226)
ARTG (117)
Australian Public Assessment Report (AusPAR) (40)
Prescription medicine registration (17)
Designation or determination (5)
Prescription medicine decision summary (3)
Prescription medicine evaluation (3)
Face mask cancellation (1)

Date

2024 (10)
2023 (18)
2022 (62)
2021 (12)
2020 (60)
2019 (31)
2018 (27)
2017 (24)
2016 (11)
2015 (51)
2014 (24)
2013 (9)
2012 (6)
2011 (4)
2010 (7)
2009 (3)
2008 (6)
2007 (6)
2006 (3)
2005 (4)
2004 (1)
2003 (3)
2002 (3)
2001 (1)
2000 (3)
1999 (4)
1998 (5)
1997 (4)
1995 (1)
1992 (2)
1991 (6)

Results for "[search-keyword]"

Search

Sponsor content

412 result(s) found, displaying 181 to 190

AVANDIA rosiglitazone 4mg (as maleate) tablet film coated blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2019

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
AVANDIA rosiglitazone 2mg (as maleate) tablet film coated blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2019

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
AusPAR: Tafenoquine (as succinate)

15 November 2018

Australian Public Assessment Report (AusPAR)

Australian Public Assessment for Tafenoquine (as succinate)
PRIORIX VACCINE 0.5mL injection vial and diluent syringe Cancelled under Section 30(1)(c) of the Act

5 April 2019

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
PRIORIX VACCINE 0.5mL injection vial and diluent ampoule Cancelled under Section 30(1)(c) of the Act

5 April 2019

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
AVANDIA rosiglitazone 8mg (as maleate) tablet film coated blister pack Cancelled under Section 30(1)(c) of the Act

5 April 2019

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
PRIORIX VACCINE injection vial (10 x 0.5mL) Cancelled under Section 30(1)(c) of the Act

5 April 2019

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
ZOVIRAX aciclovir 200mg tablet bottle Cancelled under Section 30(1)(c) of the Act

5 April 2019

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
ZOVIRAX aciclovir 400mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

5 April 2019

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
STIEVA-A 0.1% tretinoin 1mg/g cream tube Cancelled under Section 30(1)(c) of the Act

5 April 2019

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd

Pages

First page
Previous page
…
Page 15
Page 16
Page 17
Page 18
Current page 19
Page 20
Page 21
Page 22
Page 23
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.